IDYA News & Events

Ideaya Biosciences announced first-patient-in for a Phase 1 clinical trial combination study to evaluate IDE849, a delta-like ligand 3-targeting Topo-I-payload antibody drug conjugate program, and IDE161, a poly glycohydrolase inhibitor. The Phase 1 combination study will be evaluated in DLL3 upregulated solid tumor indications, including small cell lung cancer, neuroendocrine tumors, neuroendocrine carcinomas and melanoma.

Ideaya Biosciences provided updated guidance related to the timing of its upcoming topline data release from the Phase 2/3 OptimUM-02 trial in first-line HLA-A2-negative metastatic uveal melanoma. The database lock is projected in the first half of April, followed by the topline data analysis thereafter. A live investor and analyst webcast will be hosted by Ideaya management and a guest key opinion leader, the company said.

Ideaya Biosciences is down -6.0%, or -$1.96 to $30.79.

Ideaya Biosciences announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an investigational MTA-cooperative PRMT5 inhibitor being developed for patients with MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE892 as a monotherapy agent and in combination with IDE397, Ideaya's MAT2A inhibitor, in mid-2026. Dual inhibition of IDE892 and IDE397 has demonstrated durable and well-tolerated tumor regressions in preclinical MTAP-deleted tumor models, including in NSCLC.